HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Abstract
Depsipeptide (FR901228) is a bicyclic peptide isolated from Chromobacterium violaceum that has demonstrated potent in vitro cytotoxic activity against human tumor cell lines and in vivo efficacy against human tumor xenografts. The primary mechanism of action is through inhibition of histone deacetylase. Initial development was halted due to significant cardiac toxicity. Subsequent studies performed at the National Cancer Institute demonstrated administration without cardiotoxicity was possible by varying the schedule of administration. A phase I trial was designed to determine the maximum tolerated dose and toxicity profile when administered as a 4-hour infusion weekly x 3 with one week rest. 33 Patients with advanced, incurable cancers were enrolled into this trial and treated with doses of Depsipeptide ranging from 1 mg/m2 to 17.7 mg/m2. At doses above 5 mg/m2, we observed common symptoms of nausea, vomiting, fatigue, and anorexia. Subtle changes in ECGs were seen in several patients. However, no cardiac enzyme abnormalities or reduction in ejection fraction were observed. The MTD was defined as 13.3 mg/m2 with dose limiting toxicities being grade 3 thrombocytopenia and fatigue. Depsipeptide can be safely administered when given as a 4-hour infusion and further clinical trials are warranted.
AuthorsJohn L Marshall, Naiyer Rizvi, John Kauh, William Dahut, Manuela Figuera, Min H Kang, William D Figg, Irving Wainer, Christoff Chaissang, Megan Zhaoyang Li, Michael J Hawkins
JournalJournal of experimental therapeutics & oncology (J Exp Ther Oncol) 2002 Nov-Dec Vol. 2 Issue 6 Pg. 325-32 ISSN: 1359-4117 [Print] United States
PMID12440223 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibiotics, Antineoplastic
  • Depsipeptides
  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Peptides, Cyclic
  • romidepsin
Topics
  • Adult
  • Aged
  • Antibiotics, Antineoplastic (administration & dosage, adverse effects, pharmacokinetics)
  • Depsipeptides
  • Electrocardiography
  • Enzyme Inhibitors (administration & dosage, adverse effects, pharmacokinetics)
  • Fatigue (chemically induced)
  • Female
  • Histone Deacetylase Inhibitors
  • Humans
  • Infusions, Intravenous
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Neoplasms (drug therapy, metabolism)
  • Peptides, Cyclic (administration & dosage, adverse effects, pharmacokinetics)
  • Therapeutics
  • Thrombocytopenia (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: